Table III.
Efficacy and safety results for cryo-laser cryo-sclerotherapy (CLaCS) and foam
| Variable | Group | No.a | Mean | SD | Min | Median | Max | P valueb |
|---|---|---|---|---|---|---|---|---|
| ΔE intensity | CLaCS | 21 | 1.3 | 1.88 | 0.12 | 0.8 | 9.1 | .02735 |
| Foam | 21 | 1.44 | 1 | 0 | 1.1 | 3.4 | ||
| ΔE intensity FP III/IV | CLaCS | 20 | 0.91 | 0.61 | 0.12 | 0.75 | 2.2 | .006 |
| Foam | 20 | 1.48 | 1.01 | 0 | 1.11 | 3.4 | ||
| Reduction rate, % | CLaCS | 21 | 62.34 | 25.65 | 10 | 62.5 | 100 | .3475 |
| Foam | 21 | 68.45 | 26.68 | 20 | 63.64 | 100 | ||
| Sclerosant volume | CLaCS | 23 | 0.5 | 0.6 | 0.1 | 0.3 | 3 | <.0001 |
| Foam | 23 | 1.85 | 0.73 | 0.5 | 2 | 3 | ||
| Vein punctures | CLaCS | 23 | 4.52 | 1.75 | 1 | 4 | 10 | .9966 |
| Foam | 23 | 3.13 | 1.42 | 2 | 3 | 6 | ||
| Pain score, cm | CLaCS | 23 | 2.72 | 1.48 | 0.2 | 2.3 | 6.5 | .9885 |
| Foam | 23 | 1.85 | 1.14 | 0.5 | 1.75 | 5 |
FP, Fitzpatrick skin type classification; Max, maximum value; Min, minimum value.
a
No. varies due to participant loss to follow-up.
b
P value calculated using Wilcoxon statistical test for comparisons between the Foam and ClaCs groups.